Rural survivors were more likely to experience chronic pain than urban survivors, at rates of 43.0% and 33.5%, respectively. After controlling for several factors, the investigators found that rural ...

Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation ...

Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting. Researchers determined the BrECADD combination ...

The Food and Drug Administration (FDA) has approved Rybrevant Faspro™, a subcutaneous (SC) formulation of amivantamab for all indications approved for the ...

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

In this analysis of colorectal cancer patients from 2 clinical trials, researchers aimed to assess the effect of physical activity on overall survival.

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL. Researchers determined zanubrutinib plus obinutuzumab demonstrated sustained ...

Our most popular articles from the San Antonio Breast Cancer Symposium address the role of carboplatin in survival outcomes; findings that may enable women to undergo less-invasive surgical procedures ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.